MAP Pharma (MAPP) NOt Rquired by U.S. FDA to Perform Second Pivotal Effecacy for LEVADEX NDA Submission
Tweet Send to a Friend
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
